ABSTRACT

In the present investigation an attempt has been made to enhance the solubility and dissolution rate, thereby increasing bioavailability and improved patient compliance by developing extended-release tablets of Oxcarbazepine. Oxcarbazepine co-crystals were prepared with co- formers like benzoic acid, tartaric acid and oxalic acid. The efficient co-crystals were further directly compressed to extended-release tablets with various rate controlling polymers like chitosan, HPMC K10M, Carbopol 940. The prepared tablets were evaluated for Pre compression and Post compression studies and results were found to be within acceptable limits. The drug excipient compatibility studies were confirmed by FTIR and DSC. The In- vitro dissolution studies were performed for the prepared tablets and observed that formulation containing 8% chitosan shows the release of the drug about 82.4% for 8 hrs and it follows zero- order release mechanism with non-fickian super case-II transport. The developed formulation shows 63% similarity with marketed product. Stability studies wereconducted for formulation (F2) at 40ºC ± 5% RH for a period of 1 month and results were found to be within the limits. Hence the formulation F2 wasconsidered as best formulation. Key words: Oxcarbazepine, co-crystals, extended-release tablets, direct compression, rate controlling polymers
Publication date: 01/07/2026

https://www.ijbpas.com/pdf/2026/July/MS_IJBPAS_2026_10239.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2026/15.7.10239